Liraglutide was the first GLP-1 receptor agonist approved for chronic weight management, and for most of the past decade it was the only one. Then semaglutide and tirzepatide arrived, delivered substantially more weight loss on a weekly rather than daily injection, and the market moved on almost completely.
Two things have made liraglutide relevant again. Novo Nordisk has given advance notice that it will discontinue Saxenda, its brand of liraglutide 3 mg, with last shipments to wholesalers in late January 2027. And in August 2025 the FDA approved the first generic liraglutide injection for long-term weight management.
If you are on Saxenda today, you need a plan. If liraglutide is the right molecule for you clinically — and for some patients it genuinely is — you need to know where it will still be available. This guide covers both.
It also covers the question worth asking honestly: for many patients affected by the discontinuation, the right answer is not another source of liraglutide but a switch to a weekly agent. We have set out where the balance falls.
What Is Actually Happening to Liraglutide
Saxenda Is Being Discontinued
Novo Nordisk has provided advance notice that it will discontinue Saxenda, with last shipments to wholesalers taking place in late January 2027. This is a manufacturer decision, not a supply disruption — the product is being withdrawn.
A Generic Was Approved in August 2025
The FDA approved the first generic liraglutide injection for long-term weight management in adults with obesity, or overweight with weight-related conditions. It works the same way as the brand, and it is the natural continuity route.
The Generic Has Not Collapsed the Price
Generic liraglutide has been listed around $1,084 for a comparable quantity, against a Saxenda list price of $1,349.02 for a five-pen package. Cheaper, but not the order-of-magnitude drop generic approval often implies.
Liraglutide Is Still a Daily Injection
Seven injections a week rather than one. That is a materially different adherence proposition from semaglutide or tirzepatide, and it is worth weighing honestly before committing to staying on the molecule.
It Generally Produces Less Weight Loss
Liraglutide typically delivers less weight loss than weekly semaglutide or tirzepatide. That gap is the honest reason the market moved on, and it should feature in any decision about where to go next.
Saxenda Was Approved Down to Age 12
The FDA extended Saxenda’s approval to patients aged 12 and older. Paediatric approvals in this class remain limited, so for adolescent patients the discontinuation is a more consequential change than for adults.
How We Evaluated Liraglutide Routes
✅ Regulatory Status
Whether the product is FDA-approved, a generic of an approved product, or a compounded preparation with no agency review.
💵 Total Monthly Cost
The all-in figure including any membership or care fee, not just the medication line.
📆 Continuity
Whether the route will still exist after Saxenda’s last shipments in late January 2027.
🔬 Sourcing Transparency
For compounded routes, whether the dispensing pharmacy is named and its licensure category disclosed.
🏥 Clinical Support
What ongoing access is included, which matters more for a daily injection than a weekly one.
🔄 Switching Options
Whether the provider can move you to a weekly agent without changing providers, if that turns out to be the better path.
Generic Liraglutide
The FDA approved the first generic liraglutide injection in August 2025 for long-term weight management in adults with obesity, or overweight with weight-related conditions. It works the same way as Saxenda, and it carries full FDA review of safety, efficacy and manufacturing quality.
This is the cleanest answer for a patient who is doing well on liraglutide and simply needs the brand replaced. No change of molecule, no change of route, no compounded regulatory uncertainty.
The disappointment is price. Listed around $1,084 for a comparable quantity against a Saxenda list price of $1,349.02, the generic is cheaper but has not delivered the collapse patients often expect. Price it at your own pharmacy, and check whether insurance covers the generic where it declined the brand.
✓ Why It Ranks Here:
- • FDA-approved generic with full agency review
- • Same molecule, same mechanism as Saxenda
- • Available through standard pharmacy channels
- • No compounded regulatory uncertainty
- • May be covered where insurance declined the brand
⚠ Considerations:
- • Around $1,084 — not dramatically cheaper than the brand
- • Still a daily injection
- • Still less weight loss than weekly agents
- • Insurance coverage for weight indications remains inconsistent
Hone Health
Hone Health is a hormone-health and longevity platform, and it is one of the very few providers offering compounded liraglutide — listed from $160 per month plus a membership fee, with a Basic membership at $25 per month and a Premium tier at $155.
For a patient who wants to stay on liraglutide at a fraction of brand or generic pricing, this is the main compounded route available. At $160 plus a $25 Basic membership, the all-in figure of $185 is well below the roughly $1,084 generic listing.
Hone also lists a compounded liraglutide-naltrexone combination from $60 per month. Treat that one carefully: naltrexone is approved in combination with bupropion in Contrave, not with liraglutide, and there is no FDA review behind this specific pairing. Ask for the clinical rationale rather than selecting it on price.
✓ Why It Ranks Here:
- • One of very few compounded liraglutide sources
- • From $160/month plus membership, far below brand pricing
- • Low $25 Basic membership tier available
- • Hormone care and weight care on one platform
- • Independent coverage reports semaglutide and tirzepatide also available
⚠ Considerations:
- • Compounded, not FDA-approved
- • Two-part pricing — medication plus membership
- • Membership tiers inconsistently published across sources
- • Liraglutide-naltrexone combination has no FDA review
Levity
Levity is one of the only telehealth platforms that lists brand-name Saxenda among its medication options, alongside compounded semaglutide, Ozempic, Wegovy and Mounjaro, with a clinical reviewer determining the most suitable choice.
Its structure is a single monthly fee covering medication, prescription, clinical consultation and shipping. That is a genuinely clean model — the gap is that Levity does not prominently publish the figure, so you have to request it before you can compare.
The relevance here is time-limited. With Saxenda’s last shipments to wholesalers in late January 2027, any brand-name route is a bridge rather than a destination. But it does mean a Levity patient can move between liraglutide and a weekly agent without changing providers.
✓ Why It Ranks Here:
- • One of the few telehealth platforms listing brand-name Saxenda
- • Single monthly fee covering medication, consult and shipping
- • Five medication options across brand and compounded
- • Clinical reviewer selects the medication
- • Can switch to a weekly agent without changing provider
⚠ Considerations:
- • Monthly fee not prominently published
- • Saxenda availability ends with the discontinuation
- • No compounded tirzepatide per independent coverage
- • Cancellation and refund terms not published
Nurx
Nurx lists Victoza (liraglutide), the 1.8 mg diabetes-indication formulation of the same molecule, alongside Ozempic, Wegovy, Zepbound, compounded semaglutide formulations and non-GLP-1 options including bupropion and metformin.
Victoza is not the weight-management indication — it is approved for type 2 diabetes — but it is listed around $543.51, materially below Saxenda’s $1,349.02. Whether it is appropriate for you is entirely a clinical question for your prescriber.
The fee structure is expensive: a $79 one-time consultation fee plus $79 every month, with medication billed separately and brand-name injections typically running $650 to $1,300. This route makes sense mainly if insurance covers your medication.
✓ Why It Ranks Here:
- • Lists Victoza, rarely available through telehealth
- • Very broad medication range across classes
- • Non-GLP-1 alternatives genuinely available
- • Established platform with published fee structure
- • Can switch molecules without changing provider
⚠ Considerations:
- • $79 consult plus $79/month before medication
- • Care fee is cash-pay only
- • Brand injections typically $650 to $1,300/month
- • Victoza is the diabetes indication, not weight management
Liraglutide Routes Compared
| Route | Status | Approximate Cost | Available After Jan 2027? |
|---|---|---|---|
| Saxenda (brand) | FDA-approved | $1,349.02 list, five-pen package | No — last shipments late Jan 2027 |
| Generic liraglutide | FDA-approved generic | Around $1,084 listed | Yes |
| Hone Health (compounded) | Compounded, not FDA-approved | From $160/month plus membership | Confirm directly |
| Victoza (via Nurx) | FDA-approved, diabetes indication | Around $543.51 plus fees | Yes |
| Levity (brand Saxenda) | FDA-approved | Within one monthly fee, not published | No — ends with discontinuation |
| Switch to weekly semaglutide | Compounded or brand | From $99/month compounded | Yes |
Our Recommendation
If you are on Saxenda, raise this with your prescriber now rather than in late 2026. The discontinuation is announced, the window is known, and a planned transition is far better than a rushed one when your pharmacy tells you it cannot fill your prescription.
There are three honest directions. Generic liraglutide is the cleanest continuity option if liraglutide is working for you — FDA-approved, same molecule, no compounded uncertainty, though at around $1,084 it is not cheap. Compounded liraglutide through Hone Health from $160 plus membership is the affordable route, with the trade-off that compounded preparations are not FDA-approved.
The third direction is the one worth taking seriously: switch to a weekly agent. Liraglutide generally produces less weight loss than semaglutide or tirzepatide, and requires seven injections a week rather than one. If liraglutide was chosen for you because of a specific clinical reason, that reason still applies. If it was simply what was available at the time, this is the natural moment to revisit it — and Coreage RX at a flat $99 for weekly semaglutide or tirzepatide costs a fraction of any liraglutide route.
For adolescent patients, the calculation is different. Saxenda was approved down to age 12 and paediatric approvals in this class are limited. That decision belongs entirely with the treating clinician and family, and generic liraglutide is likely the relevant continuity conversation.
Frequently Asked Questions
Why is Saxenda being discontinued?
Novo Nordisk has provided advance notice that it will discontinue Saxenda, with last shipments to wholesalers taking place in late January 2027. This is a manufacturer decision rather than a supply disruption or a safety action. A generic liraglutide injection was approved by the FDA in August 2025.
When exactly does Saxenda become unavailable?
Novo Nordisk states last shipments to wholesalers occur in late January 2027. Pharmacy stock will persist for some period after that, but you should not plan around it. Raise the transition with your prescriber well in advance.
Is generic liraglutide the same as Saxenda?
The FDA approved the first generic liraglutide injection in August 2025 for long-term weight management, and it works the same way as the brand name. It carries full FDA review of safety, efficacy and manufacturing quality, unlike compounded preparations.
How much does generic liraglutide cost?
Generic liraglutide has been listed around $1,084 for a comparable quantity, against a Saxenda list price of $1,349.02 for a five-pen package. Cheaper, but not the dramatic reduction generic approval often produces. Price it at your own pharmacy and check whether your plan covers the generic.
Should I switch to Wegovy or Zepbound instead?
For many patients, yes. Liraglutide generally produces less weight loss than weekly semaglutide or tirzepatide, and requires daily rather than weekly injection. If liraglutide was chosen for a specific clinical reason, that reason still applies — but if it was simply what was available, this is a sensible moment to revisit the choice with your clinician.
Can I get compounded liraglutide?
Yes, though sources are limited. Hone Health lists compounded liraglutide from $160 per month plus a membership fee. Compounded preparations are not FDA-approved and have not been reviewed by the agency for safety, efficacy or manufacturing quality — ask which pharmacy dispenses and whether it is 503A or 503B.
What about Victoza?
Victoza is liraglutide at the 1.8 mg dose, approved for type 2 diabetes rather than weight management, and listed around $543.51. Nurx is one telehealth platform that lists it. Whether it is appropriate for you is entirely a clinical question — it is not the weight-management indication.
What happens to adolescent patients on Saxenda?
Saxenda was approved for patients aged 12 and older, and paediatric approvals in this medication class remain limited, which makes the discontinuation more consequential for adolescent patients. Generic liraglutide is likely the relevant continuity conversation, but this decision belongs entirely with the treating clinician and family.
Disclosure:
This guide is based on publicly available information including Novo Nordisk’s published Saxenda materials and advance notice of discontinuation, FDA approval announcements for liraglutide and its first generic, provider-published pricing, and independent review coverage, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Discontinuation timelines are as announced by the manufacturer and may change. List prices are not what most patients pay — insurance coverage, savings programmes and pharmacy pricing all vary. Compounded medications are not FDA-approved and their regulatory position narrowed after semaglutide and tirzepatide left the FDA shortage list. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This guide is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
Wisp Review
One of the few platforms offering Saxenda while it remains on the market.
Trillium Meds Review
If you are switching to a weekly agent, one of the cheapest routes to it.
Saxenda Review
The original daily GLP-1, its discontinuation timeline and what comes next.
Saxenda Discontinuation Explained
What the withdrawal means for current patients and how to plan a transition.
Semaglutide vs Tirzepatide
If you are switching molecules, which weekly agent is the better fit.
Best All-Inclusive GLP-1 Providers
One price covering medication, care and shipping, at every dose.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →